|Bid||0.0000 x 2200|
|Ask||0.0000 x 2900|
|Day's Range||0.1500 - 0.2095|
|52 Week Range||0.1500 - 50.4000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Chester County gene therapy and biopharmaceutical company Ocugen has completed its previously announced reverse merger with Histogenics Corp., a publicly traded company based in Boston. Ocugen, which is developing new treatments for rare and underserved eye diseases, is now trading — at $2.50 per share Tuesday afternoon — on the Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team at Ocugen, led by Chairman and CEO Shankar Musunuri, is running the combined company which will be based in Malvern. Immediately prior to the merger, Ocugen (NASDAQ: OCGN) completed a $25 million private placement financing and Histogenics effected a reverse stock split of its common stock at a ratio of 1-for-60.
Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc. (“Ocugen”) were approved by Histogenics’ stockholders at a special meeting held on September 26, 2019. As previously announced, the proposed merger will create a public company under which the stockholders of Ocugen will become majority holders of the combined company. The proposed merger remains subject to further customary closing conditions and regulatory approvals.
BOSTON, Sept. 12, 2019 -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any.
Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any business, its special meeting of stockholders (the “Special Meeting”) to be held with respect to its proposed merger with Ocugen, Inc. (“Ocugen”) pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, as amended (the “Merger Agreement”), by and among the Company, its wholly-owned subsidiary, Restore Merger Sub, Inc. (“Merger Sub”) and Ocugen, which provides for the merger (the “Merger”) of Merger Sub with and into Ocugen. The Special Meeting is being adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX), a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On April 8th, the company announced that they have entered into a definitive merger agreement with Ocugen.
Histogenics (NASDAQ:HSGX) stock went gangbusters on Monday as the company has reportedly inked a deal with another business in the industry.Source: FlickrPennsylvania-based Ocugen is a developer of gene therapies and other biologics designed to treat rare eye diseases, and the company has agreed to a reverse merger with struggling Massachusetts-based business Histogenics. Ocugen was founded by Pfizer veteran Shankar Musunuri and University of Colorado professor Uday Kompella.The move will see Histogenics shareholders collectively hold about 10% of the new, combined company, which will include only Ocugen's lean team. However, before the former company's executives depart from the business, they will try to sell NeoCart, which is its regenerative treatment designed to treat knee cartilages.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe program was dropped by Histogenics in December as the Food and Drug Administration asked to see more data before accepting a BLA for review. Meanwhile, Ocugen's last financing round was reportedly a $7.5 million Series B closed in 2017, which added to its $6 million in Series A cash.Ocugen makes its bread and butter from drugs that arose from two platforms that were licensed from harvard's Schepens Eye Research Institute of Massachusetts Eye and Ear. One of these formulates therapies known as a nanoemulsion, which is reportedly more durable and effective than your run-of-the-mill eye drops, while the other is geared to deliver nuclear hormone receptor that goes into the retina.HSGX stock is up about 56% on Monday, while gaining another 9.3% after the bell. More From InvestorPlace * The Elite 8 Stocks to Buy for Massive Outperformance * 15 Stocks to Buy Leading the Financial Charge * 8 Best Stocks to Buy for an April Rally Compare Brokers The post Histogenics News: Why Did HSGX Stock Soar Today? appeared first on InvestorPlace.
The deal is a stock-for-stock transaction. Ocugen has a pipeline of opthalmology programs that include a modifier gene therapy platform, including OCU400 for the treatment of NR2E3-mutation associated retinal degenerative diseases.
Histogenics Corporation (HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Ocugen will become the majority owners of Histogenics’ outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly-traded, clinical-stage biopharmaceutical company operating under the Ocugen name.
HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...
Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies, today announced the appointment of Jonathan Lieber as Managing Director. With over 25 years of life science experience as a CFO and investment banker, Jon brings deep expertise to the role in service of clients at all stages of growth. “We hold ourselves to the highest standards of talent in the business, and Jon is no exception.
HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...
HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.
WALTHAM, Mass., Dec. 21, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the.
WALTHAM, Mass., Nov. 29, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...
WALTHAM, Mass., Nov. 08, 2018 -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to.
WALTHAM, Mass., Nov. 01, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.